JP2015507175A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015507175A5 JP2015507175A5 JP2014544870A JP2014544870A JP2015507175A5 JP 2015507175 A5 JP2015507175 A5 JP 2015507175A5 JP 2014544870 A JP2014544870 A JP 2014544870A JP 2014544870 A JP2014544870 A JP 2014544870A JP 2015507175 A5 JP2015507175 A5 JP 2015507175A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer cells
- prostate specific
- prostate
- steap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 33
- 210000004027 cell Anatomy 0.000 claims 32
- 206010028980 Neoplasm Diseases 0.000 claims 26
- 201000011510 cancer Diseases 0.000 claims 26
- 210000002307 prostate Anatomy 0.000 claims 24
- 239000003550 marker Substances 0.000 claims 21
- 206010060862 Prostate cancer Diseases 0.000 claims 12
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 12
- 239000003446 ligand Substances 0.000 claims 9
- 210000004369 blood Anatomy 0.000 claims 7
- 239000008280 blood Substances 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 239000003153 chemical reaction reagent Substances 0.000 claims 4
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 3
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 3
- 239000000611 antibody drug conjugate Substances 0.000 claims 3
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 210000004408 hybridoma Anatomy 0.000 claims 3
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 2
- 238000004163 cytometry Methods 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 239000006249 magnetic particle Substances 0.000 claims 2
- 244000005700 microbiome Species 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 108010093470 monomethyl auristatin E Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical group C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 102000011782 Keratins Human genes 0.000 claims 1
- 108010076876 Keratins Proteins 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 238000010820 immunofluorescence microscopy Methods 0.000 claims 1
- 239000002122 magnetic nanoparticle Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161629886P | 2011-11-29 | 2011-11-29 | |
| US61/629,886 | 2011-11-29 | ||
| US201261703099P | 2012-09-19 | 2012-09-19 | |
| US61/703,099 | 2012-09-19 | ||
| PCT/US2012/066998 WO2013082249A2 (en) | 2011-11-29 | 2012-11-29 | Compositions and methods for prostate cancer analysis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015507175A JP2015507175A (ja) | 2015-03-05 |
| JP2015507175A5 true JP2015507175A5 (cg-RX-API-DMAC7.html) | 2016-01-28 |
| JP6219304B2 JP6219304B2 (ja) | 2017-10-25 |
Family
ID=47324459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014544870A Active JP6219304B2 (ja) | 2011-11-29 | 2012-11-29 | 前立腺癌分析のための組成物及び方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20130143237A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2786151B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6219304B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101951514B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104067127A (cg-RX-API-DMAC7.html) |
| AR (1) | AR089028A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012345926A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014012882A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2854042A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL232466A (cg-RX-API-DMAC7.html) |
| MX (1) | MX350807B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2641968C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201402711SA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013082249A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201403110B (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2530505B2 (ja) | 1990-03-20 | 1996-09-04 | 三ツ星ベルト株式会社 | 自着層付き防水シ―トの製造法 |
| CN105646661A (zh) * | 2014-03-24 | 2016-06-08 | 朱育盼 | 特异性结合前列腺癌的短肽pcp2及其应用 |
| EP3286565B1 (en) * | 2015-04-21 | 2025-01-15 | Genentech, Inc. | Compositions and methods for prostate cancer analysis |
| AU2018247767B2 (en) | 2017-04-03 | 2025-01-30 | F. Hoffmann-La Roche Ag | Antibodies binding to STEAP-1 |
| CN108179134B (zh) * | 2017-12-27 | 2020-11-24 | 武汉大学 | 基于EpCAM/PSMA双抗体功能化微流控芯片及其制备方法和应用 |
| CA3104386A1 (en) | 2018-07-02 | 2020-01-09 | Amgen Inc. | Anti-steap1 antigen-binding protein |
| WO2021046331A1 (en) * | 2019-09-05 | 2021-03-11 | Memorial Sloan Kettering Cancer Center | Anti-steap1 antibodies and uses thereof |
| BR102020013625A2 (pt) * | 2020-07-02 | 2022-01-11 | Universidade Federal de Uberlândia | Aptâmero modificado, sistema aptaimunológico, painel aptaimunológico, kit, método e uso no diagnóstico de câncer de próstata |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US5597531A (en) | 1985-10-04 | 1997-01-28 | Immunivest Corporation | Resuspendable coated magnetic particles and stable magnetic particle suspensions |
| FI903489A0 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5698271A (en) | 1989-08-22 | 1997-12-16 | Immunivest Corporation | Methods for the manufacture of magnetically responsive particles |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6046048A (en) * | 1996-01-09 | 2000-04-04 | Genetech, Inc. | Apo-2 ligand |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| BR9907852A (pt) | 1998-02-12 | 2000-10-24 | Immunivest Corp | Processos para detectar e enumerar células raras e cancerosas em uma população celular mista, para diagnosticar câncer de estágio precoce em um paciente de teste, para determinar a probabilidade de recorrência de câncer em um paciente humano anteriormente tratado de câncer, para distinguir um carcinoma confinado ao órgão de um carcinoma com propriedades metastáticas, para acompanhar a situação de remissão em um paciente humano com câncer que passa pelo tratamento de terapia contra o câncer e para aumentar quantidades de células epiteliais circulantes em uma amostra de sangue, partìcula magnética revestida, composição, conjuntos de teste para avaliar uma amostra de paciente quanto a presença de células raras circulantes, quanto a presença de células de tumor circulantes, quanto a presença de células de câncer de mama circulantes, quanto a presença de células de câncer de próstata circulantes, quanto a presença de células de câncer de cólon circulantes, quanto a presença de células de câncer de bexiga circulantes e para monitorar um paciente quanto a recorrência de câncer, e, fração de sangue periférico enriquecido quanto a células neoplásticas circulantes |
| US6200765B1 (en) * | 1998-05-04 | 2001-03-13 | Pacific Northwest Cancer Foundation | Non-invasive methods to detect prostate cancer |
| JP4855577B2 (ja) | 1998-06-01 | 2012-01-18 | アジェンシス，インコーポレイテッド | ヒト癌で発現される新規蛇行性膜貫通抗原およびその使用 |
| IL129299A0 (en) * | 1999-03-31 | 2000-02-17 | Mor Research Applic Ltd | Monoclonal antibodies antigens and diagnosis of malignant diseases |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| KR20030080002A (ko) | 2001-02-16 | 2003-10-10 | 이뮤니베스트 코포레이션 | 순환 암 세포를 신속하고 효과적으로 분리하기 위한 방법및 시약 |
| US20030190602A1 (en) * | 2001-03-12 | 2003-10-09 | Monogen, Inc. | Cell-based detection and differentiation of disease states |
| US7219016B2 (en) * | 2001-04-20 | 2007-05-15 | Yale University | Systems and methods for automated analysis of cells and tissues |
| US7494646B2 (en) | 2001-09-06 | 2009-02-24 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
| US8008442B2 (en) * | 2004-04-22 | 2011-08-30 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| RU2483080C2 (ru) | 2006-10-27 | 2013-05-27 | Дженентек, Инк. | Антитела и иммуноконъюгаты и их применение |
| WO2008058239A2 (en) * | 2006-11-08 | 2008-05-15 | The Regents Of The University Of Michigan | Spink1 as a prostate cancer marker and uses thereof |
| JP5394246B2 (ja) * | 2007-03-30 | 2014-01-22 | ジェネンテック， インコーポレイテッド | 抗体及びイムノコンジュゲートとこれらの使用方法 |
| EP2335075A4 (en) * | 2008-09-05 | 2011-12-14 | Scripps Research Inst | METHOD FOR DETECTING CIRCULATING TUMOR CELLS |
| EP2558109A4 (en) | 2010-04-16 | 2014-09-24 | Bellicum Pharmaceuticals Inc | METHOD FOR TREATING HARD TUMORS |
-
2012
- 2012-11-29 CN CN201280067510.XA patent/CN104067127A/zh active Pending
- 2012-11-29 JP JP2014544870A patent/JP6219304B2/ja active Active
- 2012-11-29 SG SG11201402711SA patent/SG11201402711SA/en unknown
- 2012-11-29 KR KR1020147017563A patent/KR101951514B1/ko active Active
- 2012-11-29 AR ARP120104485A patent/AR089028A1/es unknown
- 2012-11-29 RU RU2014126358A patent/RU2641968C2/ru not_active IP Right Cessation
- 2012-11-29 MX MX2014006187A patent/MX350807B/es active IP Right Grant
- 2012-11-29 AU AU2012345926A patent/AU2012345926A1/en not_active Abandoned
- 2012-11-29 CA CA2854042A patent/CA2854042A1/en not_active Abandoned
- 2012-11-29 WO PCT/US2012/066998 patent/WO2013082249A2/en not_active Ceased
- 2012-11-29 US US13/689,407 patent/US20130143237A1/en not_active Abandoned
- 2012-11-29 BR BR112014012882A patent/BR112014012882A2/pt not_active Application Discontinuation
- 2012-11-29 EP EP12798559.6A patent/EP2786151B1/en active Active
-
2014
- 2014-04-29 ZA ZA2014/03110A patent/ZA201403110B/en unknown
- 2014-05-05 IL IL232466A patent/IL232466A/en not_active IP Right Cessation
-
2015
- 2015-10-21 US US14/919,388 patent/US9632091B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015507175A5 (cg-RX-API-DMAC7.html) | ||
| Campos-Silva et al. | High sensitivity detection of extracellular vesicles immune-captured from urine by conventional flow cytometry | |
| Balitzer et al. | Autoimmune hepatitis: review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria | |
| Wang et al. | Prostate specific antigen biosensor based on long range surface plasmon-enhanced fluorescence spectroscopy and dextran hydrogel binding matrix | |
| Chatterjee et al. | Direct kinetic fingerprinting and digital counting of single protein molecules | |
| Soh et al. | CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab | |
| RU2014126358A (ru) | Композиции и способы анализа рака предстательной железы | |
| JP7022191B2 (ja) | 前立腺がんの分析のための組成物及び方法 | |
| Fathi et al. | Detection of CD133-marked cancer stem cells by surface plasmon resonance: its application in leukemia patients | |
| HRP20160461T1 (hr) | Solubilna humana st-2 antitijela i eseji | |
| JP2017518366A5 (cg-RX-API-DMAC7.html) | ||
| DuBois et al. | Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow | |
| Alston et al. | Does the addition of AMACR to CK20 help to diagnose challenging cases of urothelial carcinoma in situ? | |
| Ahuja et al. | Comparison of immunohistochemistry, cytochemistry, and flow cytometry in AML for myeloperoxidase detection | |
| Choi | Pericardial malignant mesothelioma diagnosed in a dog by immunocytochemistry of the pericardial fluid: a case report | |
| Forster et al. | Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells | |
| Sánchez-López et al. | Occult cancer in patients with unprovoked venous thromboembolism: A nested case-control study | |
| Huang et al. | Concurrent detection of cellular and molecular cancer markers using an immunomagnetic flow system | |
| Kadota et al. | Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma | |
| CN111886498A (zh) | 试剂盒、测定试剂盒及测定方法 | |
| Sangoi et al. | Variability of CD34 expression in sinonasal glomangiopericytoma: a potential diagnostic pitfall | |
| JP2018520366A5 (cg-RX-API-DMAC7.html) | ||
| Liu et al. | Evaluation of acridine orange florescence in exfoliative urinary cytology for diagnosing bladder carcinoma | |
| JP2016504590A5 (cg-RX-API-DMAC7.html) | ||
| US20170328900A1 (en) | Methods and materials for capture antibody targeted fluorescent in-situ hybridization (cat-fish) |